BR0311963A - Sistema de distribuição de droga de difusão controlada por matriz, método para produzir e para utilizar o mesmo e copolìmero de siloxano de cadeia lateral fluorada - Google Patents

Sistema de distribuição de droga de difusão controlada por matriz, método para produzir e para utilizar o mesmo e copolìmero de siloxano de cadeia lateral fluorada

Info

Publication number
BR0311963A
BR0311963A BR0311963-7A BR0311963A BR0311963A BR 0311963 A BR0311963 A BR 0311963A BR 0311963 A BR0311963 A BR 0311963A BR 0311963 A BR0311963 A BR 0311963A
Authority
BR
Brazil
Prior art keywords
drug delivery
controlled diffusion
siloxane copolymer
producing
diffusion drug
Prior art date
Application number
BR0311963-7A
Other languages
English (en)
Inventor
Joseph C Salamone
Jay F Kunzler
Daniel M Ammon Jr
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of BR0311963A publication Critical patent/BR0311963A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
    • C08G77/24—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen halogen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/04—Polysiloxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/20—Polysiloxanes containing silicon bound to unsaturated aliphatic groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/70—Siloxanes defined by use of the MDTQ nomenclature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"SISTEMA DE DISTRIBUIçãO DE DROGA DE DIFUSãO CONTROLADA POR MATRIZ, MéTODO PARA PRODUZIR E PARA UTILIZAR O MESMO E COPOLìMERO DE SILOXANO DE CADEIA LATERAL FLUORADA". Proporcionam-se sistemas de distribuição de drogas de difusão controlada por matriz copolimérica de siloxano de cadeia lateral fluorada, os quais permitem a liberação controlada de concentrações sustentadas de agentes terapêuticos dentro de uma área tratada durante um período de tempo prolongado. As características de solubilidade favoráveis das cadeias laterais fluoradas dos sistemas de distribuição de droga de difusão controlada de matriz copolimérica de siloxano permitem a manipulação das taxas de liberação de droga na dependência do uso terapêutico particular e das necessidades particulares do paciente.
BR0311963-7A 2002-06-19 2003-06-16 Sistema de distribuição de droga de difusão controlada por matriz, método para produzir e para utilizar o mesmo e copolìmero de siloxano de cadeia lateral fluorada BR0311963A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/175,716 US20040043067A1 (en) 2002-06-19 2002-06-19 Fluorosiloxane matrix controlled diffusion drug delivery systems
PCT/US2003/019026 WO2004000288A1 (en) 2002-06-19 2003-06-16 Fluorosiloxane matrix controlled diffusion drug delivery system

Publications (1)

Publication Number Publication Date
BR0311963A true BR0311963A (pt) 2005-03-29

Family

ID=29999052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311963-7A BR0311963A (pt) 2002-06-19 2003-06-16 Sistema de distribuição de droga de difusão controlada por matriz, método para produzir e para utilizar o mesmo e copolìmero de siloxano de cadeia lateral fluorada

Country Status (18)

Country Link
US (1) US20040043067A1 (pt)
EP (1) EP1515705B1 (pt)
JP (1) JP2005530842A (pt)
CN (1) CN1662227A (pt)
AU (1) AU2003238247A1 (pt)
BR (1) BR0311963A (pt)
CA (1) CA2489987A1 (pt)
CZ (1) CZ200537A3 (pt)
DE (1) DE60306379T2 (pt)
ES (1) ES2261947T3 (pt)
HK (1) HK1070826A1 (pt)
MX (1) MXPA04012897A (pt)
PL (1) PL375000A1 (pt)
RU (1) RU2307667C2 (pt)
TW (1) TW200404569A (pt)
UA (1) UA80433C2 (pt)
WO (1) WO2004000288A1 (pt)
ZA (1) ZA200409979B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765454B1 (en) 2004-07-02 2016-04-13 Mati Therapeutics Inc. Treatment medium delivery device for the eye
US7544371B2 (en) * 2005-12-20 2009-06-09 Bausch + Lomb Incorporated Drug delivery systems
US20070148244A1 (en) * 2005-12-22 2007-06-28 Kunzler Jay F Drug delivery systems
US20070218104A1 (en) * 2006-03-15 2007-09-20 Bausch & Lomb Incorporation Rate controlled release of a pharmaceutical agent in a biodegradable device
US20070218103A1 (en) * 2006-03-15 2007-09-20 Bausch & Lomb Incorporated Rate controlled release of a pharmaceutical agent in a biodegradable device
KR101062796B1 (ko) 2006-03-31 2011-09-06 큐엘티 인코포레이티드 약물 요법을 위한 비루관 배출계 임플란트
US7579021B2 (en) * 2006-09-27 2009-08-25 Bausch & Lomb Incorporated Drug delivery systems based on degradable cationic siloxanyl macromonomers
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
CN101861135A (zh) 2007-09-07 2010-10-13 Qlt栓塞输送公司 泪道植入物检测
CA2701186C (en) 2007-10-05 2017-09-19 Interface Biologics Inc. Oligofluorinated cross-linked polymers and uses thereof
EP2389221B1 (en) * 2009-01-23 2023-08-16 Mati Therapeutics Inc. Sustained released delivery of one or more agents
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CA2846384C (en) 2011-08-29 2020-12-15 Qlt Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
CA1295941C (en) * 1985-08-16 1992-02-18 Rajan Bawa Sustained-release formulation comprising a hydrophobic polymer system
US4882377A (en) * 1988-09-21 1989-11-21 Dow Corning Corporation Low-viscosity pressure-adherent silicone elastomer compositions
US5321108A (en) * 1993-02-12 1994-06-14 Bausch & Lomb Incorporated Fluorosilicone hydrogels
US5463010A (en) * 1993-11-12 1995-10-31 Surface Engineering Technologies, Division Of Innerdyne, Inc. Hydrocyclosiloxane membrane prepared by plasma polymerization process
US6322815B1 (en) * 1994-07-22 2001-11-27 W. Mark Saltzman Multipart drug delivery system
ES2191779T3 (es) * 1995-12-07 2003-09-16 Bausch & Lomb Composiciones de silicona polimeras con bajo contenido en agua y modulo reducido.
WO1997020852A1 (en) * 1995-12-07 1997-06-12 Bausch & Lomb Incorporated Monomeric units useful for reducing the modulus of silicone hydrogels
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
KR20010006026A (ko) * 1997-04-03 2001-01-15 존스 홉킨스 유니버시티 스쿨 오브 메디슨 생물분해성 테레프탈레이트 폴리에스테르-폴리(포스페이트) 중합체, 조성물, 약품 및 그의 제조방법과 이용방법
US5908996A (en) * 1997-10-24 1999-06-01 Timewarp Technologies Ltd Device for controlling a musical performance
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
CZ200537A3 (cs) 2006-04-12
CN1662227A (zh) 2005-08-31
JP2005530842A (ja) 2005-10-13
US20040043067A1 (en) 2004-03-04
WO2004000288A1 (en) 2003-12-31
ZA200409979B (en) 2006-07-26
EP1515705B1 (en) 2006-06-21
AU2003238247A1 (en) 2004-01-06
EP1515705A1 (en) 2005-03-23
TW200404569A (en) 2004-04-01
MXPA04012897A (es) 2005-03-31
RU2307667C2 (ru) 2007-10-10
DE60306379T2 (de) 2007-06-14
ES2261947T3 (es) 2006-11-16
CA2489987A1 (en) 2003-12-31
RU2005100840A (ru) 2005-07-10
PL375000A1 (en) 2005-11-14
UA80433C2 (en) 2007-09-25
DE60306379D1 (de) 2006-08-03
HK1070826A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
BR0311963A (pt) Sistema de distribuição de droga de difusão controlada por matriz, método para produzir e para utilizar o mesmo e copolìmero de siloxano de cadeia lateral fluorada
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
BRPI0411924A (pt) métodos e dispositivos para oclusão de lúmens de corpo e/ou para fornecimento de agentes terapêuticos
WO2003082188A3 (en) Methods and drug delivery systems for the treatment of orofacial diseases
BR0210628A (pt) Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
ATE464863T1 (de) Implantierbares medizinprodukt zur selektiven modulation der abgabe von mitteln in situ
TW200505402A (en) Ophthalmic drug delivery device
DE60219607D1 (de) Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
BR0115531A (pt) Tratamento de mucosites
UA81676C2 (ru) Композиция для лечения инфекций у крупного рогатого скота и свиней
ECSP045442A (es) "composiciones y metodo para el tratamiento de infección en ganado vacuno y porcino"
DE60130743D1 (de) Mikrokugeln zur aktiven embolisierung
BRPI0414017A8 (pt) pró-fármacos poliméricos de múltiplos braços
WO2007089435A3 (en) Medical devices for therapeutic agent delivery
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
AR021750A1 (es) Aparato para el tratamiento topico localizado de una enfermedad
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
GB0306977D0 (en) Device
BRPI0508053A (pt) método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto
BR0314540A (pt) Métodos para o tratamento de neurodegeneração

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.